Egyptian International Pharmaceutical Investments (CAI:PHAR) EPS (Basic) : E£6.01 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EPS (Basic)?

Egyptian International Pharmaceutical Investments's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was E£1.71. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was E£6.01.

Egyptian International Pharmaceutical Investments's EPS (Diluted) for the three months ended in Dec. 2023 was E£1.71. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was E£6.01.

Egyptian International Pharmaceutical Investments's EPS without NRI for the three months ended in Dec. 2023 was E£1.87. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 6.44.

During the past 12 months, Egyptian International Pharmaceutical Investments's average EPS without NRIGrowth Rate was 7.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 15.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Egyptian International Pharmaceutical Investments's highest 3-Year average EPS without NRI Growth Rate was 29.10% per year. The lowest was -10.40% per year. And the median was 3.70% per year.

Egyptian International Pharmaceutical Investments EPS (Basic) Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EPS (Basic) Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

5.21

3.84

3.79

4.99

5.54

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															2.06	1.46	2.13	0.71	1.71

Egyptian International Pharmaceutical Investments EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Egyptian International Pharmaceutical Investments's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(823.306	-	0)	/	148.756
	=	5.53

Egyptian International Pharmaceutical Investments's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(254.6	-	0)	/	148.756
	=	1.71

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£6.01

Egyptian International Pharmaceutical Investments (CAI:PHAR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Egyptian International Pharmaceutical Investments EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.